Anterogen Co (065660.KQ) Stock Price

Anterogen Co Price

KOSDAQ·CLOSED
13,420.00
​
Market closed

Revenue has compounded at 9.9% per year over the past 13 years to 7.54 B KRW. Earnings per share have declined at 14.8% per year over the last 5 years. Anterogen Co's net margin stands at -18.2%, down from -6.8% several years earlier.

Anterogen Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Anterogen Co business model & stock analysis

Anterogen Co., Ltd. engages in the development and sale of stem cell therapy treatments. The company is headquartered in Seoul, Seoul and currently employs 39 full-time employees. The company went IPO on 2016-02-15. is a Korea-based company mainly engaged in the manufacture of cell therapy products. The firm's product portfolio consists of Cupistem which is used for the treatment of Crohn’s fistula by using autologous adipose-derived mesenchymal stem cells; stem cell conditioned medias (SCMs), SCM2s, and Therastem-dermas which are used for strengthening the function of skin as cosmetic raw materials; Remodullins which are used for the treatment of pulmonary arterial hypertension (PAH) and other products which are used for testing services. The firm distributes its products within domestic market.

Frequently asked questions about Anterogen Co

Converted at the current exchange rate, the Anterogen Co share trades at 9.00 EUR (13,420.00 KRW).

The Anterogen Co share (065660.KQ) is listed on 1 stock exchanges, including: KOSDAQ (Seoul) (065660.KQ).

The revenue cannot currently be calculated for Anterogen Co.

The profit cannot currently be calculated for Anterogen Co.

The P/E ratio cannot be calculated for Anterogen Co at the moment.

The P/S cannot be calculated for Anterogen Co currently.

The Eulerpool Quality Score for Anterogen Co is 3/10.

The ISIN of Anterogen Co is KR7065660003. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Anterogen Co is 065660.KQ. The ticker symbol is used to trade Anterogen Co shares on the stock exchange.

Fair ValueTerminal
11,541.20 KRW
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
193.24 M KRW
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
South Korea
Currency
KRW
Initial public offering
Feb 15, 2016
ISIN
KR7065660003
Cusip
Y0R5RZ106
Market capitalization
130.60 B KRWLarge Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/Se
—
EV/EBIT
—
P/B Ratio
1.49
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-1.57 %
Last updated Nov 1, 2026, 10:20 PM

Anterogen Co Peer Group

Anterogen Co Ticker

KOSDAQ · 065660.KQ

Anterogen Co FIGI

065660:KS · BBG00BDR7X74065660:KQ · BBG00BDRGMN0

All fundamentals and in-depth analysis of Anterogen Co

Our stock analysis for Anterogen Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Anterogen Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.